Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Mangoceuticals (MGRX) over the last 3 years, with Q3 2025 value amounting to $5.5 million.

  • Mangoceuticals' Share-based Compensation rose 110866.11% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 44246.75%. This contributed to the annual value of $2.1 million for FY2024, which is 3760.58% up from last year.
  • Mangoceuticals' Share-based Compensation amounted to $5.5 million in Q3 2025, which was up 110866.11% from $3.2 million recorded in Q2 2025.
  • Mangoceuticals' Share-based Compensation's 5-year high stood at $5.5 million during Q3 2025, with a 5-year trough of $64271.0 in Q1 2023.
  • Its 3-year average for Share-based Compensation is $1.3 million, with a median of $458615.0 in 2024.
  • As far as peak fluctuations go, Mangoceuticals' Share-based Compensation plummeted by 2095.66% in 2024, and later surged by 110866.11% in 2025.
  • Over the past 3 years, Mangoceuticals' Share-based Compensation (Quarter) stood at $358901.0 in 2023, then rose by 17.79% to $422750.0 in 2024, then surged by 1211.2% to $5.5 million in 2025.
  • Its Share-based Compensation stands at $5.5 million for Q3 2025, versus $3.2 million for Q2 2025 and $1.9 million for Q1 2025.